danavorexton   Click here for help

GtoPdb Ligand ID: 11448

Synonyms: Example 5 [US10287305] | TAK-925 | TAK925
PDB Ligand
Compound class: Synthetic organic
Comment: Danavorexton (TAK-925) is an OX2 orexin receptor agonist [5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 93.32
Molecular weight 424.2
XLogP 2.83
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(=O)N1CCC[C@@H]([C@@H]1CO[C@@H]1CC[C@@H](CC1)c1ccccc1)NS(=O)(=O)C
Isomeric SMILES COC(=O)N1CCC[C@@H]([C@@H]1CO[C@@H]1CC[C@@H](CC1)c1ccccc1)NS(=O)(=O)C
InChI InChI=1S/C21H32N2O5S/c1-27-21(24)23-14-6-9-19(22-29(2,25)26)20(23)15-28-18-12-10-17(11-13-18)16-7-4-3-5-8-16/h3-5,7-8,17-20,22H,6,9-15H2,1-2H3/t17-,18+,19-,20-/m0/s1
InChI Key UXZAJSZFFARTEI-YRPNKDGESA-N
No information available.
Summary of Clinical Use Click here for help
TAK-925 was advanced to clinical trials to evaluate its effectiveness to treat hypersomnia.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03748979 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy Phase 1 Interventional Takeda
NCT04091425 Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP) Phase 1 Interventional Takeda
NCT04091438 A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia Phase 1 Interventional Takeda 3